Vicente E Torres

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8142492/publications.pdf

Version: 2024-02-01

285	29,300	3933 88	5988 160
papers	citations	h-index	g-index

290	290	290	10405
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney International Reports, 2022, 7, 117-120.	0.8	1
2	Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Kidney Medicine, 2022, 4, 100419.	2.0	8
3	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62
4	Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. , 2022, 1, .		17
5	Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 374-384.	4.5	6
6	Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2022, 33, 1087-1104.	6.1	5
7	Congenital Heart Disease in Adults with Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2022, 53, 316-324.	3.1	7
8	Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2022, 3, 465-476.	2.1	2
9	Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD. Kidney International Reports, 2022, 7, 1991-2005.	0.8	2
10	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	1.9	21
11	Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney International, 2021, 99, 977-985.	5.2	16
12	Simultaneous bilateral laparoscopic nephrectomy with kidney transplantation in patients with ESRD due to ADPKD: A singleâ€center experience. American Journal of Transplantation, 2021, 21, 1513-1524.	4.7	13
13	A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 1738-1746.	2.9	15
14	Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney International Reports, 2021, 6, 755-767.	0.8	10
15	Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 953-961.	0.8	9
16	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. Kidney International Reports, 2021, 6, 1032-1040.	0.8	0
17	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 1687-1698.	0.8	12
18	The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 1801-1812.	6.1	3

#	Article	IF	Citations
19	Semantic Instance Segmentation of Kidney Cysts in MR Images: A Fully Automated 3D Approach Developed Through Active Learning. Journal of Digital Imaging, 2021, 34, 773-787.	2.9	15
20	Functional megalin is expressed in renal cysts in a mouse model of adult polycystic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 2420-2427.	2.9	4
21	MO021ENHANCED MCP-1 RELEASE IN EARLY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
22	The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease. Kidney International, 2021, 99, 1392-1407.	5.2	32
23	High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. Kidney International Reports, 2021, 6, 1895-1903.	0.8	8
24	Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Medicine, 2021, 3, 536-545.e1.	2.0	11
25	Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy. American Journal of Kidney Diseases, 2021, 78, 282-292.	1.9	45
26	Tolvaptan in ADPKD Patients With Very Low Kidney Function. Kidney International Reports, 2021, 6, 2171-2178.	0.8	15
27	Preâ€clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB Journal, 2021, 35, e21874.	0.5	12
28	New Creatinine- and Cystatin Câ€“Based Equations to Estimate GFR without Race. New England Journal of Medicine, 2021, 385, 1737-1749.	27.0	1,236
29	Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 48-58.	4.5	26
30	Ferroptosis Promotes Cyst Growth in Autosomal Dominant Polycystic Kidney Disease Mouse Models. Journal of the American Society of Nephrology: JASN, 2021, 32, 2759-2776.	6.1	38
31	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
32	Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 69-79.	4.5	39
33	Impaired Hedgehog-Gli1 Pathway Activity Underlies the Vascular Phenotype of Polycystic Kidney Disease. Hypertension, 2020, 76, 1889-1897.	2.7	3
34	Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county. JHEP Reports, 2020, 2, 100166.	4.9	14
35	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	4.1	1
36	Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1267-1278.	4.5	24

#	Article	IF	Citations
37	Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 1640-1651.	6.1	22
38	Reactive Oxygen Species and Redox Signaling in Chronic Kidney Disease. Cells, 2020, 9, 1342.	4.1	153
39	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	1.9	23
40	Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 1, 648-656.	2.1	4
41	Oxidative Stress and Mitochondrial Abnormalities Contribute to Decreased Endothelial Nitric Oxide Synthase Expression and Renal Disease Progression in Early Experimental Polycystic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 1994.	4.1	26
42	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. American Journal of Kidney Diseases, 2020, 76, 213-223.	1.9	16
43	Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. Cellular Signalling, 2020, 72, 109649.	3.6	27
44	Large Deletions in GANAB and SEC63 Explain 2 Cases of Polycystic Kidney and Liver Disease. Kidney International Reports, 2020, 5, 727-731.	0.8	5
45	Salt, water, and vasopressin inÂpolycystic kidney disease. Kidney International, 2020, 98, 831-834.	5.2	3
46	Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. JCI Insight, 2020, 5, .	5.0	19
47	The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight, 2020, 5, .	5.0	41
48	Cystic diseases of the kidneys. , 2019, , 293-306.		0
49	ALG9 Mutation Carriers Develop Kidney and Liver Cysts. Journal of the American Society of Nephrology: JASN, 2019, 30, 2091-2102.	6.1	91
50	Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1151-1160.	4.5	34
51	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
52	Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 823-833.	4.5	25
53	Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2019, 30, 1514-1522.	6.1	67
54	Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney International Reports, 2019, 4, 1742-1748.	0.8	5

#	Article	IF	Citations
55	Identifying patientâ€important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	1.6	20
56	Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2019, 30, 1305-1313.	6.1	23
57	Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model. American Journal of Nephrology, 2019, 49, 487-493.	3.1	19
58	Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney International, 2019, 95, 1253-1261.	5.2	59
59	Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney International, 2019, 96, 159-169.	5.2	51
60	Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic. European Radiology, 2019, 29, 4843-4850.	4.5	4
61	Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease. CKJ: Clinical Kidney Journal, 2019, 12, 71-77.	2.9	9
62	Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models. Journal of the American Society of Nephrology: JASN, 2019, 30, 2113-2127.	6.1	39
63	Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in Autosomal Dominant Polycystic Kidney Disease. Pancreas, 2019, 48, 698-705.	1.1	6
64	Progress in the understanding of polycystic kidney disease. Nature Reviews Nephrology, 2019, 15, 70-72.	9.6	31
65	Threeâ€dimensional NMR microscopy of zebrafish specimens. NMR in Biomedicine, 2019, 32, e4031.	2.8	10
66	Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS. Clinical Chemistry, 2019, 65, 406-418.	3.2	16
67	Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 30-34.	0.7	21
68	Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. Journal of Clinical Investigation, 2019, 129, 4506-4522.	8.2	54
69	Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2018, 3, 619-624.	0.8	7
70	The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. American Journal of Kidney Diseases, 2018, 72, 302-308.	1.9	29
71	Tolvaptan in Later-Stage Polycystic Kidney Disease. New England Journal of Medicine, 2018, 378, 488-490.	27.0	8
72	Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney International, 2018, 93, 691-699.	5.2	76

#	Article	IF	Citations
73	A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Human Mutation, 2018, 39, 378-382.	2.5	21
74	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology Dialysis Transplantation, 2018, 33, 563-573.	0.7	28
75	Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. American Journal of Kidney Diseases, 2018, 71, 666-676.	1.9	30
76	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2018, 102, 832-844.	6.2	208
77	Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology Dialysis Transplantation, 2018, 33, 477-489.	0.7	119
78	Quantitative MRI of kidneys in renal disease. Abdominal Radiology, 2018, 43, 629-638.	2.1	37
79	Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology Dialysis Transplantation, 2018, 33, 645-652.	0.7	31
80	Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. Journal of the American Society of Nephrology: JASN, 2018, 29, 13-23.	6.1	223
81	ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. American Journal of Kidney Diseases, 2018, 71, 294-296.	1.9	5
82	Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 571-578.	6.1	101
83	Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrology, 2018, 19, 378.	1.8	11
84	Polycystic kidney disease. Nature Reviews Disease Primers, 2018, 4, 50.	30.5	435
85	A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal of the American Society of Nephrology: JASN, 2018, 29, 2458-2470.	6.1	163
86	Vasopressin Receptor Antagonism in PKD. , 2018, , 219-227.		0
87	Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1765-1776.	4.5	81
88	Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1153-1161.	4.5	60
89	Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone- System Blockade?. Current Hypertension Reviews, 2018, 14, 39-47.	0.9	13
90	Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Current Hypertension Reviews, 2018, 13, 109-120.	0.9	27

#	Article	IF	Citations
91	Role of the mechanosensitive ion channel Piezo1 in Autosomal Dominant Polycystic Kidney Disease (ADPKD). FASEB Journal, 2018, 32, 868.2.	0.5	0
92	Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, gfw060.	0.7	17
93	Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrology Dialysis Transplantation, 2017, 32, gfw294.	0.7	36
94	Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clinical and Experimental Nephrology, 2017, 21, 375-382.	1.6	7
95	Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease inÂPatients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2017, 2, 442-450.	0.8	92
96	Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial. Journal of Clinical Pharmacology, 2017, 57, 906-917.	2.0	30
97	Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2017, 45, 257-266.	3.1	15
98	B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease inÂaÂratÂmodel of polycystic kidney disease. Kidney International, 2017, 92, 657-668.	5.2	7
99	The regulatory 1Î± subunit of protein kinase A modulates renal cystogenesis. American Journal of Physiology - Renal Physiology, 2017, 313, F677-F686.	2.7	25
100	Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney International Reports, 2017, 2, 913-923.	0.8	42
101	Image texture features predict renal function decline in patients with autosomal dominantÂpolycystic kidney disease. Kidney International, 2017, 92, 1206-1216.	5.2	54
102	A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2017, 2, 451-460.	0.8	19
103	Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology: JASN, 2017, 28, 1592-1602.	6.1	78
104	Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2017, 69, 482-484.	1.9	6
105	Dietary salt restriction is beneficial to the management of autosomal dominant polycysticÂkidney disease. Kidney International, 2017, 91, 493-500.	5.2	80
106	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 92, 796-808.	5.2	40
107	Polycystic Kidney Disease and the Vasopressin Pathway. Annals of Nutrition and Metabolism, 2017, 70, 43-50.	1.9	43
108	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2017, 377, 1930-1942.	27.0	420

#	Article	IF	Citations
109	Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys. Journal of Digital Imaging, 2017, 30, 442-448.	2.9	112
110	Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1461-1469.	4.5	18
111	Tolvaptan and Kidney Pain in Patients With Autosomal DominantÂPolycystic Kidney Disease: Secondary Analysis FromÂa Randomized Controlled Trial. American Journal of Kidney Diseases, 2017, 69, 210-219.	1.9	37
112	Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology Dialysis Transplantation, 2017, 32, 1262-1262.	0.7	47
113	Generation and phenotypic characterization of Pde1a mutant mice. PLoS ONE, 2017, 12, e0181087.	2.5	29
114	Standardised Outcomes in Nephrologyâ€"Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials, 2017, 18, 560.	1.6	20
115	Isolated polycystic liver disease genes define effectors of polycystin-1 function. Journal of Clinical Investigation, 2017, 127, 1772-1785.	8.2	137
116	Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression. Nephrology Dialysis Transplantation, 2016, 31, gfv314.	0.7	40
117	GTP-binding of ARL-3 is activated by ARL-13 as a GEF and stabilized by UNC-119. Scientific Reports, 2016, 6, 24534.	3.3	34
118	Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 952-960.	0.7	54
119	Inherited renal cystic diseases. Abdominal Radiology, 2016, 41, 1035-1051.	2.1	10
120	Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. American Journal of Roentgenology, 2016, 207, 605-613.	2.2	31
121	Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial. Kidney International Reports, 2016, 1, 213-220.	0.8	37
122	The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nature Reviews Nephrology, 2016, 12, 667-677.	9.6	99
123	International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection. Nephron, 2016, 134, 205-214.	1.8	12
124	Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease. Journal of the American College of Surgeons, 2016, 223, 118-126e1.	0.5	38
125	Mutations in GANAB , Encoding the Glucosidase IIÎ± Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. American Journal of Human Genetics, 2016, 98, 1193-1207.	6.2	345
126	Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis. Liver International, 2016, 36, 595-602.	3.9	6

#	Article	IF	Citations
127	Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1290-1295.	0.7	9
128	Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 576-584.	4.5	34
129	MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 2319-2330.	6.1	62
130	Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. Magnetic Resonance in Medicine, 2016, 75, 1466-1473.	3.0	35
131	Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 2872-2884.	6.1	136
132	Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 803-811.	4.5	118
133	Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology Dialysis Transplantation, 2016, 31, 1887-1894.	0.7	46
134	Food Restriction Ameliorates the Development of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1437-1447.	6.1	138
135	Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. American Journal of Kidney Diseases, 2016, 67, 792-810.	1.9	198
136	Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. Journal of the American Society of Nephrology: JASN, 2016, 27, 1312-1320.	6.1	36
137	Volume regression of native polycystic kidneys after renal transplantation. Nephrology Dialysis Transplantation, 2016, 31, 73-79.	0.7	22
138	Native Nephrectomy in Renal Transplant Recipients With Autosomal-Dominant Polycystic Kidney Disease. Transplantation Direct, 2015, 1, e43.	1.6	29
139	Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring. Journal of Visualized Experiments, 2015, , e52757.	0.3	8
140	Effects of hydration in rats and mice with polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2015, 308, F261-F266.	2.7	47
141	Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clinic Proceedings, 2015, 90, 1030-1037.	3.0	32
142	Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model. Journal of the American Society of Nephrology: JASN, 2015, 26, 39-47.	6.1	99
143	Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American Journal of Kidney Diseases, 2015, 66, 583-590.	1.9	21
144	The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clinical and Experimental Nephrology, 2015, 19, 867-877.	1.6	54

#	Article	IF	Citations
145	Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nature Reviews Nephrology, 2015, 11, 451-464.	9.6	97
146	Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Safety, 2015, 38, 1103-1113.	3.2	155
147	Closeout of the HALT-PKD trials. Contemporary Clinical Trials, 2015, 44, 48-55.	1.8	1
148	Vasopressin Receptor Antagonists, Heart Failure, and Polycystic Kidney Disease. Annual Review of Medicine, 2015, 66, 195-210.	12.2	57
149	Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 155-164.e6.	4.4	90
150	Identification of Biomarkers for PKD1 Using Urinary Exosomes. Journal of the American Society of Nephrology: JASN, 2015, 26, 1661-1670.	6.1	106
151	Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Translational Research, 2015, 165, 488-498.	5.0	26
152	Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 160-172.	6.1	439
153	Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD. American Journal of Physiology - Renal Physiology, 2014, 306, F640-F654.	2.7	16
154	The Cleaved Cytoplasmic Tail of Polycystin-1 Regulates Src-Dependent STAT3 Activation. Journal of the American Society of Nephrology: JASN, 2014, 25, 1737-1748.	6.1	61
155	Phosphodiesterase 1A Modulates Cystogenesis in Zebrafish. Journal of the American Society of Nephrology: JASN, 2014, 25, 2222-2230.	6.1	21
156	Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney International, 2014, 85, 383-392.	5.2	37
157	Evaluating healthâ€related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver International, 2014, 34, 1578-1583.	3.9	50
158	Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 18-32.	6.1	226
159	Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2014, 371, 2267-2276.	27.0	221
160	Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2014, 371, 2255-2266.	27.0	392
161	Supervised Segmentation of Polycystic Kidneys: a New Application for Stereology Data. Journal of Digital Imaging, 2014, 27, 514-519.	2.9	9
162	Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2014, 63, 446-455.	1.9	59

#	Article	IF	Citations
163	Health-Related Quality of Life in Patients With Autosomal DominantÂPolycystic Kidney Disease and CKD Stages 1-4: AÂCross-sectional Study. American Journal of Kidney Diseases, 2014, 63, 214-226.	1.9	93
164	Regional cyst concentration as a prognostic biomarker for polycystic kidney disease. , 2014, , .		0
165	Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. Journal of Clinical Investigation, 2014, 124, 2315-2324.	8.2	261
166	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 2013, 58, 409-421.	7.3	96
167	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. Gastroenterology, 2013, 145, 357-365.e2.	1.3	76
168	Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2013, 58, 199-208.	1.9	100
169	Autosomal Dominant Polycystic Kidney Disease. , 2013, , 2645-2688.		1
170	Relationship of Copeptin, a Surrogate Marker for Arginine Vasopressin, With Change in Total Kidney Volume and GFR Decline in Autosomal Dominant Polycystic Kidney Disease: Results From the CRISP Cohort. American Journal of Kidney Diseases, 2013, 61, 420-429.	1.9	84
171	Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat. Nephrology Dialysis Transplantation, 2013, 28, 2045-2058.	0.7	7
172	Segmentation of Individual Renal Cysts from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1089-1097.	4.5	43
173	Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Current Opinion in Nephrology and Hypertension, 2013, 22, 459-470.	2.0	63
174	Novel Approach to Estimate Kidney and Cyst Volumes Using Mid-Slice Magnetic Resonance Images in Polycystic Kidney Disease. American Journal of Nephrology, 2013, 38, 333-341.	3.1	47
175	Experimental Therapies and Ongoing Clinical Trials to Slow Down Progression of ADPKD. Current Hypertension Reviews, 2013, 9, 44-59.	0.9	16
176	Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study. PLoS ONE, 2013, 8, e53016.	2.5	70
177	Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. American Journal of Physiology - Renal Physiology, 2012, 303, F1089-F1098.	2.7	17
178	Connecting the dots toward a polycystic kidney disease therapy. Nature Reviews Nephrology, 2012, 8, 66-68.	9.6	30
179	Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney International, 2012, 81, 577-585.	5.2	74
180	Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 479-486.	4.5	305

#	Article	IF	Citations
181	Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrology Dialysis Transplantation, 2012, 27, 3532-3539.	0.7	120
182	Frequency of Undiagnosed Cystic Lung Disease in Patients With Sporadic Renal Angiomyolipomas. Chest, 2012, 141, 163-168.	0.8	29
183	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2012, 367, 2407-2418.	27.0	1,267
184	Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. Journal of Clinical Investigation, 2012, 122, 4257-4273.	8.2	321
185	Characteristics of Renal Cystic and Solid Lesions Based on Contrast-Enhanced Computed Tomography of Potential Kidney Donors. American Journal of Kidney Diseases, 2012, 59, 611-618.	1.9	92
186	Cystic Diseases of the Kidney. , 2012, , 1626-1667.		4
187	Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney International, 2011, 80, 295-301.	5.2	115
188	Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2011, 57, 692-699.	1.9	115
189	Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2499-2507.	4.5	133
190	Potentially Modifiable Factors Affecting the Progression of Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 640-647.	4.5	126
191	Fibrosis, Regeneration, and Aging. Journal of the American Society of Nephrology: JASN, 2011, 22, 1393-1396.	6.1	11
192	Extended Follow-Up of Unruptured Intracranial Aneurysms Detected by Presymptomatic Screening in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1274-1285.	4.5	109
193	Epitope-Tagged Pkhd1 Tracks the Processing, Secretion, and Localization of Fibrocystin. Journal of the American Society of Nephrology: JASN, 2011, 22, 2266-2277.	6.1	67
194	Medical and surgical treatment options for polycystic liver disease1. Hepatology, 2010, 52, 2223-2230.	7.3	189
195	The HALT Polycystic Kidney Disease Trials. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 102-109.	4.5	125
196	Prospects for mTOR Inhibitor Use in Patients with Polycystic Kidney Disease and Hamartomatous Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1312-1329.	4.5	85
197	Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1052-1061.	6.1	288
198	Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease. PPAR Research, 2010, 2010, 1-8.	2.4	53

#	Article	IF	Citations
199	Cyclic nucleotide signaling in polycystic kidney disease. Kidney International, 2010, 77, 129-140.	5.2	67
200	Treatment Strategies and Clinical Trial Design in ADPKD. Advances in Chronic Kidney Disease, 2010, 17, 190-204.	1.4	46
201	Percutaneous Nephrolithotomy for Large or Multiple Upper Tract Calculi and Autosomal Dominant Polycystic Kidney Disease. Journal of Urology, 2010, 183, 183-187.	0.4	33
202	Autosomal Dominant Polycystic Kidney Disease. , 2010, , 529-542.		3
203	Autosomal Dominant Polycystic Liver Disease. , 2010, , 371-386.		1
204	Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney International, 2009, 75, 848-855.	5.2	248
205	Type II Calcimimetics and Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2009, 20, 1421-1425.	6.1	9
206	A Case for Water in the Treatment of Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1140-1150.	4.5	128
207	Vasopressin in chronic kidney disease: an elephant in the room?. Kidney International, 2009, 76, 925-928.	5.2	51
208	Autosomal dominant polycystic kidney disease: the last 3 years. Kidney International, 2009, 76, 149-168.	5.2	491
209	Characterization of PKD Protein-Positive Exosome-Like Vesicles. Journal of the American Society of Nephrology: JASN, 2009, 20, 278-288.	6.1	300
210	Polycystic Kidney Disease. Annual Review of Medicine, 2009, 60, 321-337.	12.2	697
211	Vasopressin Antagonists in Polycystic Kidney Disease. Seminars in Nephrology, 2008, 28, 306-317.	1.6	48
212	Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney International, 2008, 74, 1468-1479.	5.2	120
213	Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 631-638.	6.1	185
214	Role of Vasopressin Antagonists. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1212-1218.	4.5	42
215	Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 102-108.	6.1	240
216	Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2008, 24, 526-534.	0.7	45

#	Article	IF	Citations
217	Autosomal Dominant Polycystic Kidney Disease and Inherited Cystic Diseases. , 2008, , 2283-2313.		0
218	Comprehensive Molecular Diagnostics in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2143-2160.	6.1	372
219	Magnetic Resonance Measurements of Renal Blood Flow and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 112-120.	4.5	140
220	Increased Occurrence of Pericardial Effusion in Patients with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1223-1227.	4.5	34
221	Autosomal dominant polycystic kidney disease. Lancet, The, 2007, 369, 1287-1301.	13.7	1,170
222	Octreotide Inhibits Hepatic Cystogenesis in a Rodent Model of Polycystic Liver Disease by Reducing Cholangiocyte Adenosine 3â€²,5â€²-Cyclic Monophosphate. Gastroenterology, 2007, 132, 1104-1116.	1.3	261
223	Treatment of Polycystic Liver Disease: One Size Does Not Fit All. American Journal of Kidney Diseases, 2007, 49, 725-728.	1.9	35
224	Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy. Current Opinion in Nephrology and Hypertension, 2006, 15, 456-463.	2.0	37
225	Duodenal diverticulosis in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 3576-3578.	0.7	23
226	Cyst Number but Not the Rate of Cystic Growth Is Associated with the Mutated Gene in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 3013-3019.	6.1	230
227	Water for ADPKD? Probably, Yes. Journal of the American Society of Nephrology: JASN, 2006, 17, 2089-2091.	6.1	20
228	Comparison of Methods for Determining Renal Function Decline in Early Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 854-862.	6.1	79
229	Magnetic Resonance Imaging Evaluation of Hepatic Cysts in Early Autosomal-Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 64-69.	4.5	265
230	Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nature Clinical Practice Nephrology, 2006, 2, 40-55.	2.0	255
231	Volume Progression in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 148-157.	4.5	249
232	Volume Progression in Polycystic Kidney Disease. New England Journal of Medicine, 2006, 354, 2122-2130.	27.0	670
233	Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. Journal of Nephrology, 2006, 19, 529-34.	2.0	46
234	Vasopressin antagonists in polycystic kidney disease. Kidney International, 2005, 68, 2405-2418.	5.2	52

#	Article	IF	Citations
235	Sonographic Assessment of the Severity and Progression of Autosomal Dominant Polycystic Kidney Disease: The Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). American Journal of Kidney Diseases, 2005, 46, 1058-1064.	1.9	104
236	Effectiveness of Vasopressin V2 Receptor Antagonists OPC-31260 and OPC-41061 on Polycystic Kidney Disease Development in the PCK Rat. Journal of the American Society of Nephrology: JASN, 2005, 16, 846-851.	6.1	292
237	[Ca ²⁺] _i Reduction Increases Cellular Proliferation and Apoptosis in Vascular Smooth Muscle Cells. Circulation Research, 2005, 96, 873-880.	4.5	89
238	Therapies to Slow Polycystic Kidney Disease. Nephron Experimental Nephrology, 2004, 98, e1-e7.	2.2	39
239	Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney International, 2004, 65, 1621-1627.	5.2	90
240	Cyclic AMP, at the hub of the cystic cycle. Kidney International, 2004, 66, 1283-1285.	5.2	48
241	Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney International, 2004, 66, 1766-1773.	5.2	68
242	Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nature Genetics, 2004, 36, 575-577.	21.4	263
243	Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Medicine, 2004, 10, 363-364.	30.7	438
244	Biliary Dysgenesis in the PCK Rat, an Orthologous Model of Autosomal Recessive Polycystic Kidney Disease. American Journal of Pathology, 2004, 165, 1719-1730.	3.8	105
245	Clinical profile of autosomal dominant polycystic liver disease. Hepatology, 2003, 37, 164-171.	7.3	197
246	Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort1. Kidney International, 2003, 64, 1035-1045.	5.2	353
247	EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney International, 2003, 64, 1573-1579.	5.2	123
248	Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease11Thomas Andreoli, M.D., served as Guest Editor for this paper.. Kidney International, 2003, 64, 2214-2221.	5.2	91
249	Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Medicine, 2003, 9, 1323-1326.	30.7	597
250	Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet, The, 2003, 361, 2196-2201.	13.7	198
251	Mutations in PRKCSH Cause Isolated Autosomal Dominant Polycystic Liver Disease. American Journal of Human Genetics, 2003, 72, 691-703.	6.2	187
252	Analysis of the Polycystins in Aortic Vascular Smooth Muscle Cells. Journal of the American Society of Nephrology: JASN, 2003, 14, 2280-2287.	6.1	90

#	Article	IF	Citations
253	PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression. Human Molecular Genetics, 2003, 12, 685-698.	2.9	54
254	Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells. Human Molecular Genetics, 2003, 12, 1875-1880.	2.9	156
255	Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Human Molecular Genetics, 2003, 12, 2703-2710.	2.9	287
256	The Position of the Polycystic Kidney Disease 1 (PKD1) Gene Mutation Correlates with the Severity of Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 1230-1237.	6.1	195
257	A complete mutation screen of the ADPKD genes by DHPLC. Kidney International, 2002, 61, 1588-1599.	5.2	149
258	The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nature Genetics, 2002, 30, 259-269.	21.4	683
259	Management of Cerebral Aneurysms in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 269-276.	6.1	187
260	Long-Term Ammonium Chloride or Sodium Bicarbonate Treatment in Two Models of Polycystic Kidney Disease. Nephron Experimental Nephrology, 2001, 9, 171-180.	2.2	41
261	The pck rat: A new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney International, 2001, 59, 126-136.	5.2	163
262	Treatment prospects for autosomal-dominant polycystic kidney disease. Kidney International, 2001, 59, 2005-2022.	5.2	44
263	Vascular Expression of Polycystin-2. Journal of the American Society of Nephrology: JASN, 2001, 12, 1-9.	6.1	109
264	Complications of Autosomal Dominant Polycystic Kidney Disease in Hemodialysisâ€ƒPatients. Seminars in Dialysis, 2000, 13, 30-35.	1.3	3
265	Hypertension, proteinuria, and progression of autosomal dominant polycystic kidney disease: Where do we go from here?. American Journal of Kidney Diseases, 2000, 35, 547-550.	1.9	10
266	Chronic subdural hematoma in autosomal dominant polycystic kidney disease. American Journal of Kidney Diseases, 2000, 35, 40-43.	1.9	53
267	Identification of a Locus for Autosomal Dominant Polycystic Liver Disease, on Chromosome 19p13.2-13.1. American Journal of Human Genetics, 2000, 67, 1598-1604.	6.2	95
268	Quantification and Longitudinal Trends of Kidney, Renal Cyst, and Renal Parenchyma Volumes in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2000, 11, 1505-1511.	6.1	112
269	Identification and Characterization of Polycystin-2, thePKD2 Gene Product. Journal of Biological Chemistry, 1999, 274, 28557-28565.	3.4	329
270	Somatic Mutation in Individual Liver Cysts Supports a Two-Hit Model of Cystogenesis in Autosomal Dominant Polycystic Kidney Disease. Molecular Cell, 1998, 2, 247-251.	9.7	192

#	Article	IF	Citations
271	New insights into polycystic kidney disease and its treatment. Current Opinion in Nephrology and Hypertension, 1998, 7, 159-170.	2.0	45
272	Laparoscopic Marsupialization of Symptomatic Polycystic Kidney Disease. Journal of Urology, 1996, 156, 22-27.	0.4	53
273	Intracranial cysts in autosomal dominant polycystic kidney disease. Journal of Neurosurgery, 1995, 83, 1004-1007.	1.6	73
274	Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology, 1995, 108, 487-494.	1.3	171
275	Renal ammonia in autosomal dominant polycystic kidney disease. Kidney International, 1994, 45, 1745-1753.	5.2	31
276	Effect of Sodium Chloride, Enalapril, and Losartan on the Development of Polycystic Kidney Disease in Han:SPRD Rats. American Journal of Kidney Diseases, 1994, 24, 491-498.	1.9	74
277	Renal Stone Disease in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 1993, 22, 513-519.	1.9	148
278	Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney International, 1992, 42, 364-373.	5.2	122
279	Effect of Inhibition of Converting Enzyme on Renal Hemodynamics and Sodium Management in Polycystic Kidney Disease. Mayo Clinic Proceedings, 1991, 66, 1010-1017.	3.0	67
280	Treatment of Highly Symptomatic Polycystic Liver Disease. Annals of Surgery, 1990, 212, 30-37.	4.2	96
281	Hepatic Cyst Infection in Autosomal Dominant Polycystic Kidney Disease. Mayo Clinic Proceedings, 1990, 65, 933-942.	3.0	132
282	Natriuretic Response to Volume Expansion in Polycystic Kidney Disease. Mayo Clinic Proceedings, 1989, 64, 509-515.	3.0	30
283	Epidemiology of Adult Polycystic Kidney Disease, Olmsted County, Minnesota: 1935â€“1980. American Journal of Kidney Diseases, 1983, 2, 630-639.	1.9	347
284	Vesicoureteral Reflux in the Adult. III. Surgical Correction: Risks and Benefits. Journal of Urology, 1983, 130, 882-886.	0.4	21
285	Modulation of Cyclic Nucleotides in Isolated Rat Glomeruli. Journal of Clinical Investigation, 1978, 62, 1334-1343.	8.2	69